Found Enhances Weight Care with Affordable Semaglutide Option

Found Expands Access to Needle-Free Semaglutide

Found, a leading telehealth platform dedicated to specialized weight care, is excited to announce significant updates to its medication offerings, including the introduction of affordable compounded oral semaglutide dissolving tablets. This innovative needle-free alternative is not only easy to use, as it requires no refrigeration but also offers a competitive price point of just $189 for a four-week supply. These changes directly address the prevalent challenges of needle aversion, logistical issues, and cost constraints that many patients face.

Understanding the Shift in Weight Care

Since its establishment, Found has successfully served over 250,000 patients and has conducted more than one million consultations focused on medication-assisted weight loss strategies. The organization strives to provide personalized care designed by some of the country’s leading obesity specialists. As the need for effective weight care solutions continues to grow, Found recognizes the need to adapt and expand its offerings to better align with patient lifestyles.

Breaking Down Barriers with Needle-Free Options

With the addition of sublingual semaglutide, Found is taking a bold step forward in reducing barriers to treatment. This new medication form allows for comprehensive care, helping to lower entry barriers for those who may have previously hesitated to seek help.

Key Innovations in Weight Management

Among the numerous advantages of incorporating sublingual semaglutide, a few key innovations stand out:

• Comprehensive Care: Found’s extensive medication toolkit now includes more than a dozen options tailored to meet individual patient needs.
• Affordable Access: With an accessible price of $189 for a four-week dose, the new offering helps improve affordability in weight care solutions.
• Clinical Oversight: Each patient benefits from physician-supervised monitoring and dosing optimization, ensuring personalized care.
• Outcomes Insights: This initiative generates valuable real-world insights into the efficacy and patient experiences with alternative delivery methods.

Insights from Experts at Found

Dr. Rekha Kumar, Chief Medical Officer at Found, emphasizes the importance of evolving treatment options: "While the introduction of injectable GLP-1 medications revolutionized obesity treatment, significant barriers still remain for many. Our new oral formulation aims to break through these obstacles by providing an alternative that fits personal lifestyles, while our supportive care team works closely with each member to navigate their unique treatment pathway."

Commitment to Personalized Care

Found is dedicated to creating a holistic approach for weight management. Here’s how they aim to support members:

• Access to a robust medication formulary with over 12 treatment options customized for individual needs.
• Expert clinical oversight by clinicians trained specifically in obesity management.
• Support from a dedicated care team for seamless medication management.
• One-on-one lifestyle coaching to empower members in adopting sustainable habits.
• Tools for tracking progress and engaging educational resources that foster community support.

The Future of Weight Care at Found

CEO Luca Ranaldi stated, "With today's announcement, we reinforce our commitment to empowering the over 70% of Americans affected by overweight or obesity. By expanding our formulary to include sublingual semaglutide, we are redefining the delivery of personalized weight care to make it accessible at scale."

The new sublingual semaglutide program is set to be available soon for eligible patients. For more details on Found’s holistic approach to personalized weight management, explore their platform for an in-depth look at innovative weight care solutions.

About Found

Founded in 2019, Found is a physician-designed weight care platform that is disrupting traditional weight management approaches. By providing patients with one of the largest medication formularies and comprehensive behavior change support, Found delivers evidence-based, judgment-free care. Recognized as one of the top weight loss programs by major publications, the platform continues to advocate for sustainable health transformation.

Frequently Asked Questions

What is the main advantage of Found's new sublingual semaglutide?

The primary benefit is the removal of barriers such as needle anxiety, refrigeration needs, and high costs, making treatment more accessible.

How does Found support personalized weight care?

Found provides individualized treatment plans created by obesity specialists, ensuring tailored monitoring and medication management, plus lifestyle coaching.

Why are personalized treatment options important in weight management?

Personalized options allow for better adherence to treatment, as they align with individual lifestyles and preferences, ultimately leading to more effective outcomes.

Who can benefit from the sublingual semaglutide option?

Eligible patients who prefer a needle-free medication route for weight management will find this option beneficial.

How is Found expanding its reach in weight care?

By continuously evolving its medication offerings and focusing on innovative treatment methods, Found is committed to reaching more patients nationwide.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.